

---

**COMBINED DECLARATION AND POWER OF ATTORNEY**

**(ORIGINAL, DESIGN, NATIONAL STAGE OF PCT, SUPPLEMENTAL, DIVISIONAL,  
CONTINUATION, OR C-I-P)**

---

As a below named inventor, I hereby declare that:

**TYPE OF DECLARATION**

This declaration is for a(n) nonprovisional application.

**INVENTORSHIP IDENTIFICATION**

My residence, post office address and citizenship are as stated below, next to my name. I believe that I am an original, first and joint inventor of the subject matter that is claimed, and for which a patent is sought on the invention entitled:

**TITLE OF INVENTION**

**CARDIOVASCULAR SYSTEM ASSOCIATED PROTEIN KINASE 2 (CSAPK-2) ANTIBODIES**

**SPECIFICATION IDENTIFICATION**

The specification was filed on January 10, 2001, as Serial No. 09/757,982.

**ACKNOWLEDGMENT OF REVIEW OF PAPERS AND DUTY OF CANDOR**

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information, which is material to patentability as defined in 37, Code of Federal Regulations, Section 1.56, and which is material to the examination of this application, namely, information where there is a substantial likelihood that a reasonable Examiner would consider it important in deciding whether to allow the application to issue as a patent.

**CLAIM FOR BENEFIT OF EARLIER U.S./PCT APPLICATION(S)  
UNDER 35 U.S.C. SECTION 119 or 35 U.S.C. SECTION 365**

I hereby claim the benefit, under Title 35, United States Code, Section 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate or Title 35, United States Code, Section 365(a) of any PCT international application which designated at least one country other than the United States of America, and have also identified below, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

**PRIOR FOREIGN APPLICATIONS OR U.S. PROVISIONAL APPLICATIONS  
DESIGNATING THE U.S. FOR BENEFIT UNDER 35 U.S.C. SECTION 119:**

FOREIGN APPLICATION NO.	FILING DATE	Country	Priority Claimed	Status

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

PROVISIONAL APPLICATION NO.	FILING DATE			
60/099,657	September 9, 1998			

**CLAIM FOR BENEFIT OF EARLIER U.S./PCT APPLICATION(S)  
UNDER 35 U.S.C. SECTION 120**

I hereby claim the benefit, under Title 35, United States Code, Section 120, of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose information that occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application.

**PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS  
DESIGNATING THE U.S. FOR BENEFIT UNDER 35 U.S.C. SECTION 120:**

U.S. APPLICATIONS		Status		
U.S. APPLICATIONS	U.S. FILING DATE	Patented	Pending	Abandoned
09/163,115	September 29, 1998		Pending	
PCT APPLICATION DESIGNATING THE U.S.				
PCT APPLICATION NO.	PCT FILING DATE	U.S. APPLICATION NOS. ASSIGNED (IF ANY)		

**POWER OF ATTORNEY**

I hereby appoint the following practitioner(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

APPOINTED PRACTITIONER(S)	REGISTRATION NUMBER(S)
Scott A. Brown	32,724
Ian R. Silverman	37,443
Jean M. Silveri	39,030
Allan N. Kutzenko	38,945
Janice M. Klunder	41,121
Kerri Pollard Schray	47,066
Tracy M. Sioussat	50,609
Paul J. Paglierani	52,498

**SEND CORRESPONDENCE TO**

Jean M. Silveri  
Millennium Pharmaceuticals, Inc.  
75 Sidney Street  
Cambridge, MA 02139

**DIRECT TELEPHONE CALLS TO:**

Jean M. Silveri  
(617) 679-7336

**DIRECT FACSIMILE CORRESPONDENCE TO:**

Jean M. Silveri  
617-551-8820

---

**DECLARATION**

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Susan L. Acton

Inventor's signature

Date

Residence Lexington, Massachusetts, 02421

Post Office Address 42 Munroe Road, Lexington, Massachusetts 02421

Country of Citizenship United States

Practitioner's Docket No. MNI-050DV10 (MPI98-052P1RDV10M)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Susan Acton  
Application No.: 09/757,982 1652  
Filed: January 10, 2001 Monshipouri, M.  
For: PROTEIN KINASE MOLECULES AND USES THEREFOR

Commissioner for Patents  
Box 1450  
Alexandria, VA 22313-1450

REVOCATION OF PRIOR POWERS OF ATTORNEY  
AND APPOINTMENT OF NEW POWER OF ATTORNEY

Dear Sir:

MILLENNIUM PHARMACEUTICALS, INC., the Assignee of the entire right, title and interest in the above-identified application by virtue of the Assignment document filed with the United States Patent and Trademark Office on February 16, 1999, at Reel 9762, Frame 0552 hereby revokes all Powers of Attorney with respect to that application heretofore granted and appoints the below listed attorneys with full power of substitution and revocation to prosecute this application and to transact all business in the Patent Office connected therewith.

---

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

☐ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)


37 C.F.R. SECTION 1.10\*

☐ with sufficient postage as first class mail.

☐ as "Express Mail Post Office to Addressee"  
Mailing Label No. \_\_\_\_\_

TRANSMISSION

☒ transmitted by facsimile to the Patent and Trademark Office.

  
Signature

Date: June 6, 2003

Diana Gentile  
(type or print name of person certifying)

**\*WARNING:** Each paper or fee filed by "Express Mail" **must** have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Practitioner's Docket No. MNI-050DV10 MPI98-052P1RDV10M

Scott A. Brown, Reg. No. 32,724; Ian R. Silverman, Reg. No. 37,443; Jean M. Silveri, Reg. No. 39,030; Allan N. Kutzenco, Reg. No. 38,945; Janice M. Klunder, Reg. No. 41,121; Theodore R. Allen, Reg. No. 41,578; Kerri Pollard Schray, Reg. No. 47,066, Tracy M. Sioussat, Reg. No. 50,609; and Paul J. Paglierani, Reg. No. 52,498

all of Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, Massachusetts 02139, United States of America.


Please direct all future correspondence to:

Intellectual Property Group  
MILLENNIUM PHARMACEUTICALS, INC.  
75 Sidney Street  
Cambridge, MA 02139

and direct all telephone calls to Jean M. Silveri at 617-679-7336.

MILLENNIUM PHARMACEUTICALS, INC.

By: \_\_\_\_\_



Typed Name: Jean M. Silveri

Title: Associate General Counsel

Dated: June 6, 2003

BEST AVAILABLE COPY